Valeant Pharmaceuticals (NYSE:VRX) has gotten some of the Street excited after a much-needed third quarter beat to re-ignite confidence after a string of litigations and investigations came to haunt the giant. Yet, what makes Wells Fargo analyst David Maris dismiss market enthusiasm as overblown?
More recent articles about Valeant:
- Ex-Harvard Endowment Bosses Make Surprise Bet on Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Say Goodbye to Valeant Pharmaceuticals Intl Inc (VRX)
- Investing Guru Jim Simons Rolls Out the Red Carpet for Valeant Pharmaceuticals, Cuts Opko Health
- Tim Chiang Stays Sidelined When It Comes to Valeant Pharmaceuticals Intl Inc's (VRX) Recovery, but Sings the Praises of Bausch & Lomb Business
- Wall Street Billionaire Ken Griffin Takes a Chance on Volatile Biotech Players Valeant and Teva